Although there have been a multitude of studies, the mechanisms of angiogenesis remain incompletely understood. Increasing evidence suggests that cellular redox homeostasis is an important regulator of angiogenesis. The thioredoxin (TRX) system functions as an endogenous antioxidant that can exert influence over endothelial cell function via modulation of cellular redox status. It has become apparent that the cytosolic TRX1 isoform participates in both canonical and novel angiogenic signaling pathways and may represent an avenue for therapeutic exploitation. Recent studies have further identified a role for the mitochondrial isoform TRX2 in ischemia-induced angiogenesis. TRX-interacting protein (TXNIP) is the endogenous inhibitor of TRX redox activity that has been implicated in growth factor-mediated angiogenesis. As TXNIP is strongly induced by glucose, this molecule could be of consequence to disordered angiogenesis manifest in diabetes mellitus. This review will focus on data implicating the TRX system in endothelial cell homeostasis and angiogenesis.
A ngiogenesis is a tightly controlled process originally observed during embryogenesis as new blood vessels arise from the primitive vascular plexus. Postnatal angiogenesis is now a recognized adaptive response to ischemia and hypoxia, in which the thioredoxin (TRX) system is increasingly implicated. 1, 2 Angiogenesis may also be dysregulated-a key feature of tumor growth and other diseases, including atherosclerosis and the vascular complications arising from diabetes mellitus. Despite holding great promise, the ability to regulate angiogenesis therapeutically remains a largely unrealized goal.
The endothelial cell (EC) is central to angiogenesis. Notably, the EC senses low oxygen tensions, in part because of the inhibition of prolyl hydroxylase. Under normoxic conditions, this enzyme hydroxylates proline groups in the oxygen degradation domain of the transcription factor hypoxiainducible factor-1␣ (HIF1␣), leading to its degradation. As hypoxia inhibits prolyl hydroxylase, HIF1␣ is stabilized and can translocate to the nucleus to induce the transcription of angiogenic genes, such as vascular endothelial growth factor (VEGF). 3, 4 Cellular redox homeostasis is also an important regulator of angiogenesis. In ECs, the NADPH oxidases generate reactive oxygen species (ROS), which at low levels are important signaling moieties but at high levels have deleterious consequences. [5] [6] [7] More recent work directly implicates the TRX system and its endogenous inhibitor, TRX-interacting protein (TXNIP), in EC homeostasis and key angiogenic processes, including EC migration, proliferation, and survival. 8 -11 Herein, we review the TRX system with a particular focus on the emerging evidence of its critical role in the modulation of angiogenesis.
The TRX System
In conjunction with glutathione (GSH) and glutaredoxin, the TRX system maintains the reducing environment of the cell and detoxifies ROS. The antioxidant activity of the TRX system is primarily exerted by peroxiredoxins, which are reduced by TRX to enable scavenging of ROS. 12 The TRX system is reproduced in distinct cellular compartments; in the cytosol and nucleus, it is found the traditionally described TRX1 isoform, whereas in the mitochondria, it is found the more recently identified TRX2 isoform. Homozygous knockout of either isoform in mouse is embryonically lethal, 13, 14 and TRX molecules are retained throughout evolution, indicating that the TRX system is essential for life. [15] [16] [17] [18] Both isoforms are ubiquitously expressed and contain the highly conserved (Trp-Cys-Gly-Pro-Cys) catalytic motif that reduces oxidized proteins and ROS. In concert with these oxidoreductases are the selenium-dependent enzymes, TRX reductase-1 (TRXR1) and TRX reductase-2 (TRXR2), which use the electron donor NADPH to regenerate the TRX isoforms ( Figure 1A ). The ability of both TRX1 and TRX2 to undergo reversible oxidation may be modulated by TXNIP, which interacts with the catalytic motif to form a stable mixed disulfide that inhibits TRX activity ( Figure 1B ). This property has led to the notion that TXNIP is the endogenous inhibitor of the TRX system, a finding that has been confirmed in multiple cell types in vitro 19 -21 but not consistently recapitulated in vivo. 22, 23 The ability of TRX1 and TRX2 to interact with cysteine residues across a host of proteins entrenches the TRX system in a diverse range of cellular processes supra to its canonical role as a cytoprotective measure against oxidative stress. These include protein structure/folding, reductive and metabolic enzymes, energy utilization, transcription factors, and immune modulation. 24 The report that TRX1 was associated with increased tumor angiogenesis in a murine xenograft model 11 has since led a number of investigators to explore the role of the TRX system in angiogenesis. Recent studies involving transgenic animal models and whole genome microarray analyses have enhanced our understanding of the role for the TRX system in angiogenesis, although significant gaps in our knowledge also remain.
TRX1 and Angiogenesis
TRX1 is a 12-kDa ubiquitous oxidoreductase originally isolated in Escherichia coli as a hydrogen donor for ribonucleotide reductase 16 that is the rate-limiting enzyme in DNA synthesis ( Figure 2 ). Homozygous knockout of Trx1 results in absorption of conceptuses after implantation, with cells derived from the inner cell mass unable to proliferate ex vivo. 13 Conversely, mice overexpressing Trx1 develop normally, although they exhibit greater resistance to ischemic neuronal injury 25 and adriamycin-induced cardiotoxicity. 26 These data suggest that TRX1 expression conveys a cytoprotective effect to a variety of stressors, enhancing cell survival and function. TRX1 may also regulate key EC activities relevant to Figure 1. The TRX system. A, TRX in the oxidized (TRX-S 2 ) or reduced (TRX-(SH) 2 ) state. In the reduced state, TRX directly reduces disulfides in oxidized substrate proteins (PR Ϫ -S 2 ). The resultant oxidation of TRX in this process is reversible and maintained by thioredoxin reductase (TRXR) and the electron donor NADPH. B, TXNIP can form a mixed disulfide with reduced TRX, inhibiting the ability of TRX to reduce disulfides of other protein substrates or undergo reversible oxidation.
Figure 2.
The TRX system and angiogenesis. TRX1 and its endogenous inhibitor TXNIP are involved in multiple signaling pathways and cellular processes that come together in mediation of angiogenesis. TRX1 can modulate cell growth and proliferation by transcriptional mechanisms including redox factor-1 (REF1), and activator protein-1 (AP1), and NF-B; reductive inhibition of the growth suppressor PTEN; and modulating DNA synthesis through activation of ribonucleotide reductase. In ECs, TRX1 prevents von Hippel-Lindau (pVHL)mediated degradation of the transcription factor HIF1␣, leading to induction of VEGF expression. The VEGF signaling cascade results in the phosphorylation of Akt and eNOS to produce NO, whose release facilitates key angiogenic events, including proliferation, migration, and collateralization. TRX1 can enhance EC migration by promoting MMP action to degrade extracellular matrix. Apoptosis, an important feature of vascular remodeling, is modulated through the interaction of either cytosolic TRX1 or mitochondrial TRX2 with ASK1 and competitively inhibited by TXNIP. TXNIP can act as a metabolic switch inhibiting glycolysis and reducing NADH levels. A reduction in NADH prevents Akt activation and permits TRX activation of PTEN to inhibit proliferation. TXNIP competitively inhibits Jab1-mediated nuclear export of p27kip1 leading to cell cycle arrest. TXNIP can suppress VEGF levels possibly by TRX1-dependent (dashed line) or TRX1-independent mechanisms. A role for the arrestin domains of TXNIP in EC angiogenic signaling remains unclear (dashed line).
physiological and tumor angiogenesis, including EC migration, proliferation and vascular network formation, and apoptosis and cell survival.
TRX1 affects a number of transcriptional pathways relevant to EC angiogenic function ( Figure 2 ). Activation of the transcription factor nuclear factor-B (NF-B) modulates a variety of angiogenesis-related proteins and genes, including Akt activation of VEGF that is critical for EC migration, proliferation, and survival. 27, 28 In the cytoplasm TRX1 blocks NF-B activation by preventing its nuclear translocation, whereas in the nucleus TRX1 increases NF-B transactivation through reduction of the Cys62 residue of the p50 DNA binding motif. 29, 30 Thus, TRX1 can modulate NF-B activity to upregulate or downregulate angiogenic gene transcription. Redox factor-1 is a transcriptional coactivator in the HIF1␣ complex that binds to the VEGF promoter, 31, 32 and TRX1 has been demonstrated to enhance the binding activity of redox factor-1 to the transcription factors fos, jun, and activator protein-1 (AP1). [33] [34] [35] The action of HIF1␣ is enhanced by TRX1 redox activity, with overexpression of TRX1 leading to increased HIF1␣, VEGF, and nitric oxide synthase-2 expression in cancer cell lines. 11 Nitric oxide (NO) production from VEGF signaling and endothelial nitric oxide synthase (eNOS) activation directly facilitates proangiogenic events, including migration and proliferation. 36, 37 The production of NO further enhances TRX activity by S-nitrosylation at Cys69, thereby increasing posttranscriptional proangiogenic signaling. 38 The ability of TRX1 to interact with these transcription factors and undergo favorable posttranslational modification is consistent with a central role for the TRX system in angiogenesis signaling.
Apoptosis and cell survival are important components of angiogenesis and vascular remodeling that can be modulated by the TRX system and ROS. TRX1 interacts with apoptosis signaling kinase-1 (ASK1), preventing its homodimerization and suppressing its proapoptotic function by flagging ASK1 for ubiquitin-mediated degradation ( Figure 2 ). 39, 40 The interaction between TRX1 and ASK1 is dependent on TRX1 existing in the reduced state, with oxidation of TRX1 causing dissociation from ASK1. 39, 40 Activation of ASK1 is reinforced by sustained elevated concentrations of ROS that induce cathepsin-D degradation of TRX1, whereas short-term exposure to low concentrations of ROS induces TRX1 expression and is antiapoptotic. 41 In response to ROS and oxidative damage, ASK1 activates c-Jun N-terminal kinases (JNK) and p38 mitogen activated protein kinases, leading to EC apoptosis and death. Indeed, when ASK1 is overexpressed in human ECs, VEGF-induced cell migration and vascular network formation are inhibited. 42 However, disparate phenotypes are reported when ASK1 is deleted in mice. In one study, Ask1 null mice exhibited increased limb perfusion and VEGF receptor-2 signaling in a hindlimb ischemia model. 43 By contrast, another study demonstrated that Ask1 deletion reduces ischemia-induced neovascularization and VEGF expression in the hindlimb ischemia model. 44 To date, the reasons underlying these conflicting observations are unclear.
TRX1 and VEGF are overexpressed in a variety of cancers, including mesothelioma, 45 lung cancer, 46 colorectal cancer, 47,48 liver cancer, 49 prostate cancer, 50 breast cancer, 11 and leukemia. 51 Elevated levels of TRX1 correlate with poor prognosis. 46, 48, 52 When MCF7 breast carcinoma cells overexpressing TRX1 are xenotransplanted in mice there is increased formation of solid tumors, whereas cells overexpressing a redox-impaired C32S/C35S TRX1 mutant have reduced tumorigenicity. 53 Murine lymphoma xenografts overexpressing TRX1 also form solid tumors with enhanced capillary networks and increased VEGF levels. 11 The TRX1 inhibitor AW464 was found to impair TRX1 and HIF1␣ activity and, specifically, to reduce EC proliferation and vascular network formation in vitro. 54 Treatment of breast and colon cancer cells with the TRX1 signaling inhibitors pleurotin and PX-12 decreased TRX1 levels and activity, inhibited increases in the HIF1␣ protein, and reduced levels of VEGF, ultimately resulting in decreased tumor capillary density. 55 Blockade of TRX1 using the putative anticancer drug PX-12 has shown promising results in phase I clinical trials, with decreased plasma concentrations of the angiogenic growth factor VEGF noted in PX-12-treated patients. 56 TRX1 can also affect the extracellular matrix. Matrix metalloproteinases (MMPs) are secreted by ECs and play a critical role in angiogenesis and tumor invasion by degrading the extracellular matrix. 57 MMP activity is inhibited by tissue inhibitors of metalloproteinases. TRX1 has been shown to downregulate tissue inhibitors of metalloproteinases and to differentially regulate MMPs in a number of cell types including ECs. 58 -60 Administration of exogenous Trx at concentrations sufficient to inhibit tissue inhibitors of metalloproteinase-1 and -2 stimulated SK-N-SH neuroblastoma cell invasion in vitro. 59 In toto, these studies demonstrate a role for TRX1 in tumor angiogenesis and a potential role for TRX1 modulation in cancer treatment.
Targeted pharmacological or genetic induction of TRX1 activity may prove useful in therapeutic modulation of angiogenesis in cardiovascular disease. For example, in a rat myocardial infarct model, the red-wine compound resveratrol was demonstrated to enhance ischemia-mediated angiogenesis via TRX1 induction. 61 Subsequent increases in expression of VEGF and the stress response enzyme heme oxygenase-1 were associated with enhanced angiogenesis and improved cardiac function. 61 Resveratrol or exogenous TRX1 administration alone also increased EC vascular network formation in a Matrigel assay in vitro. Furthermore, in a similar myocardial infarction model in diabetic rats, adenoviral expression of TRX1 in the myocardium enhanced ischemiamediated angiogenesis and was associated with improvement in myocardial function. 62 Intramyocardial TRX1 gene therapy increased heme oxygenase-1 and VEGF expression. In this model, TRX1-mediated induction of VEGF expression was inhibited by the heme oxygenase-1 inhibitor, tin protoporphyrin, indicated a heme oxygenase-1-dependent effect. 62 In addition to induction of ischemia-mediated neovascularization, the cardioprotective effects of TRX1 in the context of myocardial infarction may also be related to a number of its other actions, including its direct antiapoptotic effects, its protective role against ROS-mediated cytotoxicity, 63 and its role in enhancing myocardial ischemic adaptation and thereby protecting the heart from ischemia/reperfusion injury. 64 These initial studies indicate that modulation of the TRX system in ischemic myocardium represents an avenue of future investigation.
Mitochondrial TRX2 and Ischemia-Induced Neovascularization
Mitochondrial dysfunction and excessive ROS generation are apparent in cardiovascular disease, leading to perturbations in endothelial function and apoptotic signaling, in part by inhibiting NO bioavailability. As deletion of TRX2 is embryonically lethal, coinciding with mitochondrial maturation stage 14 TRX2 may play a regulatory role in the spectrum of endothelial function, including angiogenesis. Indeed, in EC-specific Trx2 transgenic mice, both NO bioavailability and mitochondrial ROS scavenging are increased, and there is an overall reduction in oxidative stress. 65 When crossed with Apolipoprotein E-null mice, atherosclerotic lesions are reduced. Subsequent investigations demonstrated that ECspecific Trx2 transgenesis enhance both angiogenesis and arteriogenesis in a murine model of hindlimb ischemia. 8 Induction of ASK1-dependent apoptosis by ROS is reduced in ECs isolated from Trx2 transgenics. When Trx2 transgenics are crossed with eNOS knockout mice (which have a severely impaired ischemia-induced angiogenic response) Trx2 overexpression dramatically abrogates the deleterious eNOS-null phenotype. These data demonstrate a role for TRX2 in facilitating ischemia-induced angiogenesis. The recent observation that TRX2 reduces hypertension and ROS-generating NADPH oxidases emphasizes the importance of the TRX system in the broader context of endothelial biology. 66 
TRX Reductases
TRXR1 and TRXR2 are selenium-dependent enzymes localized to the cytosol and mitochondria, respectively. In mouse, the TrxR1-or TrxR2-null phenotype is embryonically lethal, 67,68 and short interfering RNA (siRNA)-mediated knockdown of TRXR1 renders ECs susceptible to oxidative stress and apoptosis. 69 TRXR1 is also implicated in angiogenesis, and the TRXR1 inhibitor PX-916 displays marked anticancer activity with reductions in TRX1 activity, HIF1␣, and VEGF levels in tumors. 70 A number of gold compounds that directly inhibit TRXR1 activity have been demonstrated to impair EC angiogenic processes. For example, auranofin can reduce EC proliferation and is implied to have antiangiogenic activity in rheumatoid arthritis, 71, 72 and a gold phosphine complex has been demonstrated to inhibit angiogenesis in zebrafish. 73 Intriguingly, although selenium is a necessary cofactor for TRXR proangiogenic activity, excessive selenium has been demonstrated to impair microvessel formation and VEGF production in mammary carcinomas and induce apoptosis in human umbilical vein ECs, 74 with selenium depletion increasing VEGF production and angiogenesis in ECs. 75 The reasons underlying this contradiction remain unclear, but it could be due to as yet unidentified compensatory mechanisms that are induced by excessive or depleted selenium. To date, no studies have explicitly examined the role of mitochondrial TRXR2 in angiogenesis, although it is speculated to have roles in the endothelium. 76 
TXNIP as a Modulator of Angiogenesis Signaling
TXNIP was isolated as a 50-kDa vitamin D 3 -inducible protein (vitamin D 3 upregulated protein-1) by yeast 2-hybrid screen for TRX1-interacting proteins in cervical cancer cells. 77 This interaction requires that TRX1 is in the reduced state 78, 79 and is significant in that TXNIP is the only currently known endogenous cofactor that inhibits TRX1 and TRX2 redox activity. 79 -81 Patwari et al have elucidated that an intramolecular disulfide bond between Cys63 and Cys247 in TXNIP is susceptible to disulfide exchange with reduced TRX1 at Cys247, leading to a stable mixed disulfide ( Figure 1B) . 78, 82 Although this is yet to be confirmed by crystallography, this mixed disulfide at the catalytic motif would significantly impair the ability of TRX1 to interact with a number of proangiogenic molecules, leading to modulation of angiogenic signaling.
TXNIP has been described as a metastasis suppressor 83 that is strongly downregulated in a variety of tumor tissues and cell lines. 84 -87 Mice deficient in TXNIP also have increased incidence of hepatocellular carcinoma. 88 Conversely, when TXNIP was overexpressed in the HEp-2 epithelial cell line, xenotransplants displayed reduced tumorigenesis in mice. 89 TXNIP is known to interact with a variety of molecules to modulate cell cycle progression and growth ( Figure 2 ). Overexpression of TXNIP leads to an enhanced interaction with ␣-importin-1 (RCH1) and nuclear translocation of the complex, suppressing growth activity in MCF7 breast cancer cells. 90 TXNIP can also competitively inhibit Jab1-mediated nuclear export of p27kip1 to the cytoplasm, leading to cell cycle arrest 91 (Figure 2 ), which is critical to halting tumor progression. 92, 93 In the cytoplasm, TXNIP interacts with TRX1 and inhibits its nuclear translocation, blocking TRX1dependent gene transcription 94 and influencing the expression of cell death and survival genes. 95 The cell cycle inhibitor and tumor suppressor p21(WAF1) also suppresses TXNIP gene transcription, leading to increases in TRX activity, EC migration, vascular network formation, and invasion. 96 Recent work from our laboratory has revealed a central role for TXNIP in angiogenic growth factor-mediated EC migration. 10 To gain insights into the transcriptional events necessary for angiogenesis, we used whole genome cDNA microarray analysis to identify and characterize concordant gene expression programs triggered by administration of 3 angiogens: VEGF, basic fibroblast growth factor, and nicotine. In human microvascular ECs, TXNIP was consistently repressed by all 3 angiogenic factors. Corepression of TXNIP was associated with stimulation of TRX activity. Interestingly, hexamethomium, a nicotinic acetylcholine receptor antagonist, abrogated growth factor-related effects on TXNIP and TRX1, suggesting a role for the nicotinic acetylcholine receptor in growth factor signaling via modulation of TXNIP/ TRX1. Gene knockdown of TRX1 by siRNA abrogated the stimulatory effects of all 3 angiogenic factors on EC migration. Gene silencing of TXNIP alone, without angiogenic factors, induced TRX activity and profoundly stimulated EC migration-a proangiogenic effect. More recently, we explored the effect of TRX1/TXNIP modulation on EC migration and vascular network formation using a Matrigel assay. Downregulation of TRX1 by siRNA in human coronary artery ECs inhibited migration and vascular network formation in a Matrigel assay, whereas siRNA inhibition of TXNIP increased migration and vascular network formation. 97 Fluid shear stress is a principal trigger for arteriogenesis. Normal laminar flow has been demonstrated to inhibit TXNIP expression and increase TRX activity in rabbit aorta and ECs. 98 Shear stress also enhances S-nitrosylation and thereby the activity of TRX1, and it increases the production of NO in ECs, 99 leading to suppression of TXNIP expression in smooth muscle cells. 20 These observations implicate the TRX system, particularly TXNIP, as a regulator of biomechanical signaling in the vasculature. Interestingly, ischemia was found to induce TXNIP expression in a rat myocardial infarction model, whereas DNAzyme to TXNIP led to reduced apoptosis and improved cardiac function. 100 The mechanisms underlying the relationship between TXNIP and endothelial function require further investigation.
Despite the demonstration that TXNIP inhibits TRX activity in multiple cell types in vitro, including ECs, 10 vascular smooth muscle cells, 20 breast cancer cells, 21 lens epithelial cells, 101 and mesangial cells, 102 and in aortic tissue ex vivo, 98 this observation has not been consistently demonstrated in vivo. This is particularly true of the total and tissue-specific TXNIP knockout mice 22, 23, 103, 104 and TXNIP-deficient mouse models available, 105 which demonstrate no significant changes in TRX activity. The inability of current techniques to specifically and sensitively measure TRX redox moieties in vivo could explain this remaining controversy. Indeed, the GSH system represents the primary redox buffer, and it competes with the TRX system for reducing equivalents (NADPH). 106 Minor changes in the ratio of reduced (GSH) to oxidized glutathione (GSSG) have been noted in TXNIP-deficient mice. 107 TXNIP knockout mice have a prominent metabolic phenotype, and muscle tissues inappropriately adapt to fasting by increasing glycolysis, which leads to accumulation of nicotinamide adenine dinucleotide (NADH). 103 The accumulation of NADH activates Akt signaling and competitively inhibits TRX-nicotinamide adenine dinucleotide phosphate (NADPH)-mediated activation of the tumor suppressor phosphatase and tensin homolog (PTEN), thereby increasing cell proliferation (Figure 2 ). This increased glycolysis is reminiscent of the Warburg effect of high aerobic glycolysis in tumors, which increases HIF1␣ to stimulate tumor growth and angiogenic signaling. 108 -110 However, changes in TRX activity were not assessed in this study, 103 and the discrepancies between in vitro and in vivo models highlight a major outstanding issue in the field that needs to be addressed.
A number of cell studies and knockout mouse models have demonstrated that TXNIP is a critical regulator of glucose metabolism. 22, 23, [111] [112] [113] [114] TXNIP knockout mice exhibit a prominent metabolic phenotype characterized by hyperinsulinemia and fasting hypoglycemia. TXNIP is also a member of the arrestin family of signaling proteins 78 that have roles in a wide range of cellular processes; for example, ␤ 2 -arrestin is a mediator of insulin signaling, 115 vascular permeability, 116 and tumor angiogenesis. 117 The idea that TXNIP may exert its antiangiogenic action via TRX-independent mechanisms must therefore be considered. Indeed, TXNIP's role in glucose metabolism is a property intrinsic to the arrestin domains and not the Cys247 TRX-binding residue. 82 Delineating whether TXNIP's role in angiogenesis is via canonical pathways such as TRX1-mediated stabilization of HIF1␣ and subsequent VEGF activation or via as yet unidentified protein-protein interactions involving the arrestin domains may clarify conjecture as to TXNIP's prooxidant status in vivo.
The TRX System and Diabetes-Related Impairment of Angiogenesis
In diabetes mellitus, hyperglycemia induces ROS that contribute to the pathogenesis of diabetic vascular complications. ROS have profound effects on the vasculature, leading to endothelial dysfunction, accelerated atherosclerosis, and microvascular and peripheral arterial disease. 118 A striking characteristic of the diabetic state is the heterogeneity of angiogenic dysregulation. For example, VEGF is upregulated in the diabetic eye, whereas VEGF signaling is impaired in the peripheral arterial and microvascular environments. 119 To date, the mechanisms underlying dysregulated angiogenesis and impaired VEGF signaling in diabetes mellitus remain unclear.
Microarray studies identified TXNIP as the gene most strongly induced by glucose in pancreatic ␤ cells. 120 A carbohydrate response element within the TXNIP promoter underlies this striking feature. 121 TXNIP is induced by sugars in a variety of other cell types, including vascular smooth muscle cells, 122 ECs, 97, 123 hepatoma, 124 and breast cancer. 21 It is associated with increased apoptosis in pancreatic ␤ islets 125, 126 and cardiomyocytes by competitive inhibition of the TRX1/ASK-1 complex. 100, 127, 128 Hyperglycemic induction of TXNIP in vascular smooth muscle cells and ECs in vitro represses TRX activity, induces ROS accumulation, 122 and inhibits vascular network formation. 97 Knockdown of TXNIP by siRNA or adenoviral overexpression of TRX1 abrogates glucose-induced ROS accumulation in smooth muscle cells. 122 Furthermore, in streptozotocin-induced diabetic rats, TXNIP expression is increased in the vasculature, and TRX activity is reduced. 122 As impaired angiogenesis and endothelial dysfunction are the hallmark of diseases such as diabetes mellitus, hyperglycemia-mediated induction of TXNIP could have important consequences for ROS-induced endothelial dysfunction, impaired angiogenesis, and dysregulated biomechanical signaling.
We recently identified a critical role for hyperglycemiamediated induction of TXNIP in diabetes-related impairment of ischemia-mediated angiogenesis using a murine model of hindlimb ischemia. 129 Moreover, TXNIP knockdown to nondiabetic levels rescued diabetes-related impairment of ischemia-mediated angiogenesis and limb functional recovery. Diabetes-related inhibition of VEGF was also attenuated by TXNIP knockdown. The demonstration that adenoviral overexpression of TRX1 in the infarcted myocardium of diabetic rats enhances angiogenesis and improves cardiac function 62 is consistent with our proposal that dysregulation of the TRX system is a critical mechanism underlying disordered angiogenesis in diabetes mellitus. There also appears to be a link between diabetes mellitus and TRX2. In rats with streptozotocin-induced diabetes, aortic expression of TRX2 is reduced, and in vitro siRNA knockdown of TRX2 in ECs results in increased glucose toxicity with upregulation of the endothelial glucose transporter GLUT1. 130 As previously mentioned, the interaction between TXNIP and TRX2 within the mitochondria is particularly intriguing, 85 given the metabolic aberrations of diabetes mellitus.
Redox Homeostasis of Angiogenesis
Despite structural and functional similarities reiterated between the TRX systems such as redox metabolism and apoptosis, ablation of either of the respective TRX1/2 or TRXR1/2 isoforms results in cessation of embryogenesis, 13, 14, 68, 131 surprisingly demonstrating little functional redundancy between the 2 systems. TRX-1 has been shown to stabilize HIF1␣ protein by causing the dissociation of von Hippel-Lindau protein, thereby preventing HIF1␣ ubiquitination and degradation ( Figure 2 ). 9 However, opposing roles for TRX1 and TRX2 have been described in HEK-293 cells submitted to hypoxic treatment. 132, 133 Overexpression of TRX1 led to increased HIF1␣ accumulation and activity under hypoxia, normoxia, and NO treatments. Conversely, when TRX2 was overexpressed, hypoxia-induced HIF1␣ accumulation and activity were reduced, with increases in mitochondrial ROS. 132 Overexpression of TRXR2 also reduces NO-induced HIF1␣ accumulation and activity. 133 As mitochondria facilitate ATP production, the investigators went on to demonstrate that TRX1 expression enhances ATP levels, thereby increasing HIF1␣ protein translation, whereas TRX2 or TRXR2 overexpression attenuates ATP levels and protein translation. 133 These findings suggest an association between TRX2 and the mitochondrial respiratory chain, with ROS entering the cytosol and counterbalancing TRX1enhanced translation of HIF1␣ protein. 133 Recent studies in pancreatic ␤ cells identify TXNIP as a mechanism underlying the TRX1/TRX2 balance of power. 81 Under normal conditions, Saxena et al found TXNIP to be strongly localized to the nucleus. 81 However, under conditions of oxidative stress, TXNIP is shuttled to the mitochondria, where it out-competes ASK1 binding to TRX2, leading to induction of apoptosis via the mitochondrial pathway.
The divergent effects of the reductases TRXR1 and TRXR2 strengthen the concept that cellular homeostasis requires a delicate balance between TRX1 and TRX2. Embryos null for TrxR1 are not viable in vivo, and ECs isolated from embryos do not proliferate in vitro. 68 However, isolated cardiomyocytes are not affected, and cardiac-specific deletion does not affect embryo development. 68 By contrast, cardiacspecific TrxR2 deletion leads to cardiomyopathy and death in the embryo. 67 The independent features of the 2 TRX systems are intriguing and suggest that redox control of hypoxiamediated and metabolically mediated cellular function extends to development, as well as cellular physiology and disease.
Other antioxidants, such as GSH, have also been shown to control angiogenesis. With the increasing appreciation of cross-talk between the TRX and GSH systems 106, 134 we must also consider the role of GSH in angiogenic signaling and redox homeostasis. Similar to TRX, oxidized GSSG is reduced to GSH by glutathione reductase and NADPH. In conjunction with GSH, glutathione peroxidase (GPX) detoxi-fies H 2 O 2 . The high ratio of reduced GSH to oxidized GSSG within cells is maintained by glutathione reductase and GPX, and it is now understood that the GSH/GSSG ratio can modulate canonical angiogenic signaling molecules. 135 In squamous cell carcinoma, increased levels of GSSG were demonstrated to regulate HIF1␣ activation in the context of hypoxia. 135 Conversely, increased levels of GSH inhibited eNOS phosphorylation and NO production to impair VEGFinduced EC migration and angiogenesis in the Intercellular adhesion molecule knockout mouse. 136 Moreover, Gpx1 knockout mice have reduced angiogenesis following hindlimb ischemia, 137 and GPX4 has been demonstrated to regulate tumor angiogenesis by upregulating liopxygenases. 138 The antioxidant superoxide dismutase (SOD) detoxifies the highly damaging superoxide anion that is generated by the NADPH oxidases to H 2 O 2 , thereby reducing oxidative stress and providing a substrate that can be eliminated by GPX and peroxiredoxins. As previously mentioned, high levels of ROS can be deleterious, whereas low levels of ROS can play important signaling roles, [5] [6] [7] 139, 140 and in this regard SODderived H 2 O 2 may play a key role in angiogenesis. In transgenic SOD mice, angiogenesis is dramatically increased compared with nontransgenic mice, 141 whereas SOD overexpression in fibroblasts enhances H 2 O 2 generation and increases VEGF production. 142 Exogenous SOD has been demonstrated to localize to the EC membrane, where it generates H 2 O 2 to promote VEGF-induced VEGF receptor-2 signaling, which results in EC proliferation and migration in vitro and enhanced angiogenesis in a murine hindlimb ischemia model. 143 Although discrete roles in angiogenic signaling are evident, significant overlap in reducing equivalents, substrates, and redox moieties exist between these major antioxidant systems. Similar to the balancing act of the TRX1 and TRX2 compartments, a redox homeostasis must be maintained between the major antioxidant systems in health that is disrupted in disease. To date, the ability of the TRX1 or GSH or SOD to potentiate each other's redox systems in the context of ROSinduced angiogenic signaling remains unexplored.
Conclusion
The paradigm of TRX1 as a simple redox regulator has shifted in recent times with TRX activity proven to extend to many aspects of vascular function, including angiogenesis. In the EC, TRX1 exerts proangiogenic effects throughout a broad range of cellular activities relevant to angiogenic function, including transcription, posttranslational modification, migration, proliferation, vascular network formation, apoptosis, and intracellular signaling. Mitochondrial TRX2 also plays a critical role in ischemia-induced angiogenesis and arteriogenesis. These potent effects may be modulated by TXNIP in vitro, although the effect of TXNIP on TRX activity in vivo requires further clarification. Intriguingly, normalization of hyperglycemia-induced TXNIP expression to nondiabetic levels rescues diabetes-related impairment of ischemiamediated angiogenesis. The ability of TXNIP to further regulate cell cycle progression and metastasis clearly identifies TXNIP as an important target for therapeutic angiogenesis. The onus of future investigations rests on precisely delineating the interrelationship of these TRX system members so that effective modulation of this system as an angiogenic therapy can be realized. 
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